专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP3041928A1 COMPOSITIONS COMPRISING A MITOFUSIN INHIBITOR FOR PROMOTING CELL REPROGRAMMING AND A USE THEREOF 有权
标题翻译：包含用于促进细胞重编程的MITFUSIN抑制剂的组合物及其用途
公开(公告)号：EP3041928A1
公开(公告)日：2016-07-13
申请号：EP15721111.1
申请日：2015-04-23
申请人： Korea Research Institute of Bioscience and Biotechnology
发明人： CHO, Yee Sook , SON, Myung Jin , KWON, You Jeong
IPC分类号： C12N5/02 , C12N5/074 , C07K16/40
摘要： The present invention relates to a composition comprising a repressor of mitofusin gene expression, an inhibitor of mitofusin protein activity, or a mixture thereof as an active ingredient for promoting reprogramming a differentiated cell into a pluripotent stem cell, and a use thereof. The composition according to the present invention increases the efficiency of reprogramming as well as reduces the time required for reprogramming to produce pluripotent stem cells. Therefore, the present composition can be beneficially used to develop the production technology of high efficiency pluripotent stem cell and secure a large-scale culture system. Further, the present composition can be beneficially used to maintain pluripotent stem cells and screen the compounds capable of promoting the reprogramming into pluripotent stem cells.
摘要翻译：本发明涉及包含mitofusin基因表达阻遏物，mitofusin蛋白活性抑制剂或其混合物作为促进将分化细胞重编程为多能干细胞的活性成分的组合物及其用途。根据本发明的组合物增加了重编程的效率并且减少了重编程产生多能干细胞所需的时间。因此，本发明的组合物可以有益地用于开发高效多能干细胞的生产技术并确保大规模培养体系。此外，本发明组合物可有利地用于维持多能干细胞并筛选能够促进重编程为多能干细胞的化合物。

2. 发明公开

EP3686274A2 METHOD FOR PRODUCING NATURAL KILLER CELL AND USE THEREOF 审中-实审
公开(公告)号：EP3686274A2
公开(公告)日：2020-07-29
申请号：EP18858679.6
申请日：2018-09-21
申请人： Korea Research Institute of Bioscience and Biotechnology
发明人： CHO, Yee Sook , KIM, Han-Seop , SEOL, Binna , CHOI, In Pyo
IPC分类号： C12N5/0783 , A61K35/17
摘要： The present invention relates to a method for producing natural killer cells using direct reprogramming, natural killer cells produced thereby, a biomarker specific to the natural killer cells, a cell therapeutic agent comprising the natural killer cells, a composition for treatment and prevention of cancer, a cryopreservation cell vial for storing the natural killer cells, and a medium kit for inducing the direct reprogramming. Exhibiting excellent proliferative potential and cancer cell killing potential, the natural killer cells produced by the production method can be effectively utilized for mass production and in a composition for treatment and prevention of cancer.

3. 发明授权

EP3041928B1 COMPOSITIONS COMPRISING A MITOFUSIN INHIBITOR FOR PROMOTING CELL REPROGRAMMING AND A USE THEREOF 有权
公开(公告)号：EP3041928B1
公开(公告)日：2020-03-25
申请号：EP15721111.1
申请日：2015-04-23
申请人： Korea Research Institute of Bioscience and Biotechnology
发明人： CHO, Yee Sook , SON, Myung Jin , KWON, You Jeong
IPC分类号： C12N5/02 , C12N5/074 , C07K16/40

4. 发明公开

EP3954762A1 METHOD FOR PRODUCING NK CELLS WITH CAR GENE INTRODUCED THERETO, AND USE THEREOF 审中-公开
公开(公告)号：EP3954762A1
公开(公告)日：2022-02-16
申请号：EP20778116.2
申请日：2020-03-27
申请人： Korea Research Institute of Bioscience and Biotechnology
发明人： CHO, Yee Sook , KIM, Han-Seop , KIM, Jae Yun , SEOL, Binna
IPC分类号： C12N5/0783 , C12N15/86 , C07K14/705 , A61K35/17 , A61P35/00
摘要： The present invention relates to a method for producing induced natural killer (iNK) cells, into which a chimeric antigen receptor (CAR) gene encoding a CAR is introduced, iNK cells produced by the method, and a cell therapy composition and a pharmaceutical composition for preventing or treating cancer, comprising the iNK cells.
The method according to the present invention has the effects of producing the iNK cells, into which a CAR gene is introduced, with high efficiency through direct reprogramming from isolated cells without limiting an initial cell, and directly producing the same without a differentiation process, thereby simplifying the production process and reducing costs and time. The method according to the present invention has the effect of producing excellent NK cells having enhanced safety by directly producing NK cells from human somatic cells that are easy to obtain, without passing through induced pluripotent stem cells produced through conventional reprogramming technology. In addition, the iNK cells, into which a CAR gene is introduced, produced by the method, have an excellent cancer cell killing ability, and thus can be effectively utilized as a cell therapy composition or a pharmaceutical composition for preventing or treating cancer.

5. 发明公开

EP3950935A1 METHOD FOR PRODUCING IMMUNOCYTES, AND USE THEREOF 审中-公开
公开(公告)号：EP3950935A1
公开(公告)日：2022-02-09
申请号：EP20777770.7
申请日：2020-03-27
申请人： Korea Research Institute of Bioscience and Biotechnology
发明人： CHO, Yee Sook , KIM, Han-Seop , KIM, Jae Yun , SEOL, Binna
IPC分类号： C12N5/0783 , C12N15/86 , C07K14/705 , A61K35/17 , A61P35/00
摘要： The present invention relates to: a method for producing immunocytes, specifically induced natural killer T (iNKT) cells that are induced by direct reprogramming of isolated somatic cells, and chimeric antigen receptor (CAR)-iNKT cells into which a CAR gene encoding a CAR is introduced; iNKT cells produced by the method; and a cell therapy composition and a pharmaceutical composition for preventing or treating cancer, comprising the iNKT cells.
The method according to the present invention can produce, through direct reprogramming, iNKT cells or iNKT cells into which a CAR gene is introduced, from isolated cells so as to simplify the production process and shorten production time, thereby reducing costs, to have excellent NKT cell production efficiency, and to ensure safety according to the production without passing through induced pluripotent stem cells, thereby having an excellent NKT cell production effect distinguished from that of a conventional reprogramming technique. In addition, the iNKT cells or iNKT cells into which a CAR gene is introduced, which are produced by the method, have an excellent cancer cell killing ability, and thus can be effectively used as a cell therapy composition or a pharmaceutical composition for preventing or treating cancer.

6. 发明公开

EP3012321A1 HUMAN CELL MODEL OF GM1 GANGLIOSIDOSIS AND USE OF SAME 失效
标题翻译：男子名人赛尔莫迪尔FÜRGM1-GANGLIOSIDOSE UND VERWENDUNG DAVON
公开(公告)号：EP3012321A1
公开(公告)日：2016-04-27
申请号：EP14880388.5
申请日：2014-11-20
申请人： Korea Research Institute of Bioscience and Biotechnology
发明人： CHO, Yee Sook , SON, Mi Young , KWAK, Jae Eun , SEOL, Binna , JEON, Hye Jin
IPC分类号： C12N5/074 , C12N5/073 , C12N5/079 , A61K38/55 , A61P21/00
CPC分类号： C07K14/4703 , A61K38/55 , C07K5/0202 , C07K5/0812 , C12N5/0619 , C12N5/0656 , C12N5/0696 , C12N2501/2301 , C12N2501/602 , C12N2501/603 , C12N2501/604 , C12N2501/606 , C12N2501/70 , C12N2501/999 , C12N2506/1307 , C12N2506/45 , C12N2510/00 , G01N33/5023
摘要： The present invention relates to a method for preparing a GM1 gangliosidosis human cell model based on induced pluripotent stem cells (iPSCs) and iPSCs originated neural progenitor cells, and a use of the GM1 model above for the development of a GM1 gangliosidosis treating agent. The iPSCs originated from GM1 patient fibroblasts can be differentiated into neural progenitor cells (NPCs) and neurosphere cells that can emulate the characteristics shown in GM1 patient, so that the said cells can be efficiently used for the investigation of intracellular GM1 symptoms such as the GM1 gangliosidosis and lysosome accumulation and the gene expression pattern change. So, the GM1 cell model of the present invention can be efficiently used for the study of GM1 development mechanism and the study for the development of a therapeutic agent for the disease. The present inventors also established the inflammasome inhibitor rhIL1RA or Z-YVAD-FMK by using the above GM1 cell model and further confirmed that it can be efficiently used as a relieving/treating agent of GM1 gangliosidosis.
In addition, the molecular symptoms of GM1 patient could be reproduced in the transformed cells having the E186A mutation which is newly identified as the GM1 gangliosidosis causing protein mutation. Therefore, the mutant cells containing the induced E186A mutation can be efficiently used as the GM1 gangliosidosis cell model.
摘要翻译：本发明涉及一种基于诱导多能干细胞（iPSCs）和iPSCs起源的神经祖细胞制备GM1神经节苷脂病人类细胞模型的方法，以及上述GM1模型用于开发GM1神经节苷脂治疗药物的方法。源自GM1患者成纤维细胞的iPSCs可以分化成可以模拟GM1患者特征的神经祖细胞（NPC）和神经球细胞，使得所述细胞可以有效地用于研究细胞内GM1症状，如GM1 神经节苷脂和溶酶体积累和基因表达模式发生变化。因此，本发明的GM1细胞模型可以有效地用于研究GM1发育机制和研究用于疾病治疗剂的研究。本发明人还通过使用上述GM1细胞模型建立了炎性体抑制剂rhIL1RA或Z-YVAD-FMK，并进一步证实可以有效地用作GM1神经节苷脂的缓解/治疗剂。此外，GM1患者的分子症状可以在具有新鉴定为导致蛋白质突变的GM1神经节苷脂病的E186A突变的转化细胞中复制。因此，含有诱导的E186A突变的突变细胞可以有效地用作GM1神经节苷脂细胞模型。

7. 发明授权

EP3012321B1 HUMAN CELL MODEL OF GM1 GANGLIOSIDOSIS AND USE OF SAME 失效
公开(公告)号：EP3012321B1
公开(公告)日：2019-04-03
申请号：EP14880388.5
申请日：2014-11-20
申请人： Korea Research Institute of Bioscience and Biotechnology
发明人： CHO, Yee Sook , SON, Mi Young , KWAK, Jae Eun , SEOL, Binna , JEON, Hye Jin
IPC分类号： C12N5/074 , C12N5/073 , C12N5/079 , A61K38/55 , A61P21/00 , C07K5/02 , C07K5/087 , C07K14/47 , C12N5/0793 , C12N5/077

8. 发明授权

EP2774918B1 NOVEL LOW-MOLECULAR WEIGHT COMPOUND FOR PROMOTING PLURIPOTENT STEM CELL GENERATION, MAINTENANCE, AND PROLIFERATION, AND COMPOSITION AND CULTURING METHOD CONTAINING SAME 失效
标题翻译：低分子量新组合鼓励生产，这种文化关怀和增殖的多能干细胞，组合物及方法
公开(公告)号：EP2774918B1
公开(公告)日：2017-03-22
申请号：EP12877706.7
申请日：2012-11-08
申请人： Korea Research Institute of Bioscience and Biotechnology
发明人： CHO, Yee Sook , LEE, Kyeong , LEE, Jung Woon
IPC分类号： C07D209/20 , C12N5/0735 , C12N5/02
CPC分类号： C12N5/0696 , C07D209/18 , C07D209/20 , C07D209/24 , C07D405/12 , C12N5/0606 , C12N2500/02 , C12N2500/30 , C12N2501/115 , C12N2501/602 , C12N2501/603 , C12N2501/604 , C12N2501/606 , C12N2501/999 , C12N2506/02 , C12N2506/09

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式